Tuesday February 20, 2018

Preventing the development of Hypertension, Obesity and Diabetes in Mid-life is Necessary to Lower Heart Failure Risk

People without diabetes lived on average between 8.6 and 10.6 years longer without heart failure

0
//
87
Representational Image. Pixabay
Republish
Reprint

New York, November 29, 2016: Preventing the development of hypertension, obesity and diabetes in mid-life — between the age of 45 and 55 years — can result in an 86 per cent lower risk of heart failure throughout the remainder of life, says a research.

Millions of people worldwide currently suffer from heart failure as well as face a significantly reduced quality of life and higher mortality rate.

NewsGram brings to you current foreign news from all over the world.

The study found that hypertension, obesity and diabetes — major risk factors as well as highly prevalent in individuals — are preventable risk factors for heart failure, the researchers said.

Further, people with diabetes were found to have a particularly strong association with shorter heart failure-free survival, as those without diabetes lived on average between 8.6 and 10.6 years longer without heart failure.

NewsGram brings to you top news around the world today.

Men at age 45 years without any of the three risk factors lived an average of 10.6 years longer free of heart failure, while women at age 45 without any of the three risk factors lived an average of 14.9 years longer without heart failure.

“The study adds to the understanding of how individual and aggregate risk factor levels, specifically in middle age, affect incident heart failure risk over the remaining lifespan,” said John T. Wilkins from the Northwestern University at Evanston, in Illinois, in the US.

Check out NewsGram for latest international news updates.

Prevention of hypertension, obesity and diabetes by ages 45 and 55 years may substantially prolong heart failure-free survival, decrease heart failure-related morbidity and reduce the public health impact of heart failure, the researchers noted.

The study was published in the journal JACC: Heart Failure. (IANS)

Click here for reuse options!
Copyright 2016 NewsGram

Next Story

Common BP Drug May Prevent Onset Of Type 1 Diabetes

For the study, published in the Journal of Clinical Investigation, the team used a supercomputer, on the lab bench, in mice, and in humans

0
//
14
Type 1 Diabetes

A drug commonly used to control high blood pressure may be also effective in preventing the onset of Type 1 diabetes in up to 60 percent of those at risk, researchers say.

The drug, methyldopa, has been used for over 50 years to treat high blood pressure in pregnant women and children and is also on the World Health Organization’s list of essential drugs.

Methyldopa was found to block a molecule called DQ8 — found in some 60 percent at the risk of getting Type 1 diabetes — which significantly increases the chance of getting the disease.

Blocking specifically the DQ8 molecule could also block the onset of the disease, the study found.

 

ALSO READ: Eat According to Your Blood Type and See the Benefits Yourself!

“This is the first personalized treatment for Type 1 diabetes prevention,” said Aaron Michels, Associate Professor of medicine at University of Colorado – Anschutz.

“With this drug, we can potentially prevent up to 60 percent of Type 1 diabetes in those at the risk for the disease. This is very significant development,” Michels added.

Type 1 Diabetes

For the study, published in the Journal of Clinical Investigation, the team used a supercomputer, on the lab bench, in mice, and in humans.

They found that methyldopa not only blocked DQ8, but it did not also harm the immune function of other cells like many immunosuppressant drugs do.

ALSO READ: Diabetes can hamper your reproductive health

“We can now predict with almost 100 percent accuracy who is likely to get Type 1 diabetes. The goal, with this drug, is to delay or prevent the onset of the disease among those at risk,” Michels said.

The drug is taken orally, three times a day.

Besides, diabetes, the same approach of blocking specific molecules can be used in other autoimmune diseases such as rheumatoid arthritis, coeliac disease, multiple sclerosis, systemic lupus erythematosus and others, the researchers noted. (IANS)